trending Market Intelligence /marketintelligence/en/news-insights/trending/p7BlZ34V1jiyxSS8x4XBmg2 content esgSubNav
In This List

Novo Nordisk gets US FDA approval for diabetes drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novo Nordisk gets US FDA approval for diabetes drug

The U.S. Food and Drug Administration approved Novo Nordisk A/S' diabetes drug Ozempic.

Ozempic, or semaglutide, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The approval is based on the results from a clinical trial program, in which the drug showed reductions in body weight and also reduced glycated hemoglobin compared with placebo, sitagliptin, exenatide extended-release and insulin glargine U100.

Ozempic will be launched in the latest generation of Novo Nordisk's prefilled devices called Ozempic Pen.

Novo Nordisk will conduct a pediatric trial in adolescents under 18 years of age as part of the post-approval requirements.